These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24239535)

  • 1. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.
    Richter A; Eggenstein E; Skerra A
    FEBS Lett; 2014 Jan; 588(2):213-8. PubMed ID: 24239535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
    Skerra A
    FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticalins small engineered binding proteins based on the lipocalin scaffold.
    Gebauer M; Skerra A
    Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties.
    Skerra A
    J Biotechnol; 2001 Jun; 74(4):257-75. PubMed ID: 11526907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticalins as alternative binding proteins for therapeutic use.
    Skerra A
    Curr Opin Mol Ther; 2007 Aug; 9(4):336-44. PubMed ID: 17694446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds.
    Schiefner A; Skerra A
    Acc Chem Res; 2015 Apr; 48(4):976-85. PubMed ID: 25756749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticalins as an alternative to antibody technology.
    Schlehuber S; Skerra A
    Expert Opin Biol Ther; 2005 Nov; 5(11):1453-62. PubMed ID: 16255649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural plasticity in the loop region of engineered lipocalins with novel ligand specificities, so-called Anticalins.
    Achatz S; Jarasch A; Skerra A
    J Struct Biol X; 2022; 6():100054. PubMed ID: 34988429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin.
    Gebauer M; Schiefner A; Matschiner G; Skerra A
    J Mol Biol; 2013 Feb; 425(4):780-802. PubMed ID: 23238252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.
    Hohlbaum AM; Skerra A
    Expert Rev Clin Immunol; 2007 Jul; 3(4):491-501. PubMed ID: 20477155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticalin® proteins: from bench to bedside.
    Deuschle FC; Ilyukhina E; Skerra A
    Expert Opin Biol Ther; 2021 Apr; 21(4):509-518. PubMed ID: 33074019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.
    Rauth S; Hinz D; Börger M; Uhrig M; Mayhaus M; Riemenschneider M; Skerra A
    Biochem J; 2016 Jun; 473(11):1563-78. PubMed ID: 27029347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies.
    Schönfeld D; Matschiner G; Chatwell L; Trentmann S; Gille H; Hülsmeyer M; Brown N; Kaye PM; Schlehuber S; Hohlbaum AM; Skerra A
    Proc Natl Acad Sci U S A; 2009 May; 106(20):8198-203. PubMed ID: 19416843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticalins in drug development.
    Schlehuber S; Skerra A
    BioDrugs; 2005; 19(5):279-88. PubMed ID: 16207069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered protein scaffolds for molecular recognition.
    Skerra A
    J Mol Recognit; 2000; 13(4):167-87. PubMed ID: 10931555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).
    Barinka C; Ptacek J; Richter A; Novakova Z; Morath V; Skerra A
    Protein Eng Des Sel; 2016 Mar; 29(3):105-15. PubMed ID: 26802163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of an artificial receptor protein ("anticalin") based on the human apolipoprotein D.
    Vogt M; Skerra A
    Chembiochem; 2004 Feb; 5(2):191-9. PubMed ID: 14760740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMR structure and dynamics of the engineered fluorescein-binding lipocalin FluA reveal rigidification of beta-barrel and variable loops upon enthalpy-driven ligand binding.
    Mills JL; Liu G; Skerra A; Szyperski T
    Biochemistry; 2009 Aug; 48(31):7411-9. PubMed ID: 19603796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin.
    Schlehuber S; Beste G; Skerra A
    J Mol Biol; 2000 Apr; 297(5):1105-20. PubMed ID: 10764576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipocalins as a scaffold.
    Skerra A
    Biochim Biophys Acta; 2000 Oct; 1482(1-2):337-50. PubMed ID: 11058774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.